Keybank National Association OH raised its stake in shares of Baxter International Inc. (NYSE:BAX – Free Report) by 189.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 97,791 shares of the medical instruments supplier’s stock after buying an additional 64,052 shares during the quarter. Keybank National Association OH’s holdings in Baxter International were worth $2,347,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of BAX. BlackRock Inc. purchased a new stake in Baxter International in the second quarter worth approximately $1,744,874,000. Pzena Investment Management LLC purchased a new position in shares of Baxter International during the second quarter worth approximately $1,392,098,000. Equity Investment Corp purchased a new position in shares of Baxter International during the second quarter worth approximately $146,815,000. Bank of America Corp DE purchased a new position in shares of Baxter International during the second quarter worth approximately $132,993,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Baxter International in the 2nd quarter worth approximately $68,036,000. 90.19% of the stock is currently owned by institutional investors.
Baxter International Price Performance
BAX stock opened at $25.77 on Monday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.19 and a current ratio of 1.79. The firm has a 50 day moving average price of $24.54 and a 200-day moving average price of $21.67. Baxter International Inc. has a 52-week low of $15.73 and a 52-week high of $30.00. The firm has a market capitalization of $13.33 billion, a price-to-earnings ratio of -18.28, a PEG ratio of 3.79 and a beta of 0.68.
Baxter International (NYSE:BAX – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. The business had revenue of $2.98 billion during the quarter, compared to analyst estimates of $2.91 billion. Baxter International had a negative net margin of 6.23% and a positive return on equity of 16.23%. Baxter International’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.69 EPS. Equities research analysts forecast that Baxter International Inc. will post 2.10 EPS for the current fiscal year.
Baxter International Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Friday, November 27th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, November 27th. Baxter International’s dividend payout ratio is currently -2.84%.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on BAX. Jefferies Financial Group reaffirmed a “hold” rating and set a $25.00 price objective on shares of Baxter International in a research note on Thursday, October 29th. Barclays lifted their price objective on Baxter International from $20.00 to $23.00 and gave the stock an “underweight” rating in a report on Monday, November 9th. Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 30th. Finally, Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. One equities research analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Baxter International currently has a consensus rating of “Reduce” and an average price target of $23.27.
Check Out Our Latest Analysis on BAX
Baxter International Company Profile
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Further Reading
- Five stocks we like better than Baxter International
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX – Free Report).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
